WASHINGTON -- Federal regulators have warned more than 350 medical practices that Botox they may have received from a Canadian supplier is unapproved and could be counterfeit or unsafe.
The Food and Drug Administration says in a letter sent last week that batches of the wrinkle treatment shipped by pharmacy Canada Drugs have not been approved by the FDA and that the agency cannot assure their effectiveness or their safety.
The FDA says Canada Drugs was previously tied to shipping unapproved and counterfeit cancer drugs.
The agency warns doctors about of buying drugs from sources other than licensed U.S. pharmacies. This is the fifth warning the agency has made this year about foreign suppliers providing unapproved drugs.